Henry Adewoye - Compugen Chief Medical Officer
| CGEN Stock | ILA 740.00 4.00 0.54% |
Executive
Dr. Henry Adewoye is Chief Medical Officer of the Company. Dr. Adewoye joins Compugen from Gilead Sciences Inc., where he most recently served as Clinical Director in Oncology Clinical Research, was on the Oncology Leadership Team and held positions of increasing responsibility as Project Team and Clinical Lead for multiple Phase 13 Programs, Andecaliximab, GS9901, and Acalisib. Prior to Gilead, he was Clinical Research Medical Director in Oncology at Amgen Inc. and Global Medical Monitor for the initial registrational trial of the bispecific antibody blinatumomab and several Phase 2 and 3 studies evaluating VEGF inhibitors in patients with solid tumors. Dr. Adewoye completed his Fellowship in HematologyOncology at Boston Medical Center and completed his residency in Internal Medicine atMeharry Medical College since 2018.
| Tenure | 6 years |
| Phone | (972) 3 765 8555 |
| Web | www.cgen.com |
Compugen Management Efficiency
The company has return on total asset (ROA) of (0.2301) % which means that it has lost $0.2301 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4394) %, meaning that it generated substantial loss on money invested by shareholders. Compugen's management efficiency ratios could be used to measure how well Compugen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 8 records | EXECUTIVE Age | ||
| Assaf Kacen | Evogene | 43 | |
| Yisrael Gewirtz | Purple Biotech | 40 | |
| Avraham BenTzvi | Purple Biotech | 52 | |
| Pinhas BarShmuel | Purple Biotech | 45 | |
| Assaf Segal | Clal Biotechnology Industries | 43 | |
| Sigal Fattal | Evogene | 44 | |
| Merril Gersten | BioLine RX | N/A | |
| Leah Klapper | BioLine RX | N/A | |
Management Performance
| Return On Equity | -0.44 | |||
| Return On Asset | -0.23 |
Compugen Leadership Team
Elected by the shareholders, the Compugen's board of directors comprises two types of representatives: Compugen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Compugen. The board's role is to monitor Compugen's management team and ensure that shareholders' interests are well served. Compugen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Compugen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joshua Shemer, Independent External Director | ||
| Rivka Schwartz, VP Discovery | ||
| Paul Sekhri, Chairman of the Board | ||
| Martin Gerstel, Chairman of the Board | ||
| Zurit Levine, Vice President - Research and Discovery | ||
| Ari Krashin, Chief Financial Officer | ||
| Anat CohenDayag, President, Chief Executive Officer, Director | ||
| Ruth Arnon, Independent Director | ||
| Yair Aharonowitz, Independent External Director | ||
| Eran Dor, Gen Sec | ||
| Oliver Froescheis, Sr Devel | ||
| Alberto Sessa, Chief Officer | ||
| Michal Preminger, Director | ||
| Henry MD, VP Officer | ||
| Dov Hershberg, Director | ||
| Arie Ovadia, Independent External Director | ||
| Eran Perry, Director | ||
| Sanford Zweifach, Director | ||
| Gilead Halevy, Director | ||
| Yvonne Naughton, Head Communications | ||
| Kinneret Savitsky, Director | ||
| Henry Adewoye, Chief Medical Officer | ||
| Dorit Amitay, VP HR | ||
| JeanPierre Bizzari, Director | ||
| John Hunter, VP of Antibody RandD and Site Head of Compugen USA Inc |
Compugen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Compugen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | 12.53 M | |||
| Shares Outstanding | 86.62 M | |||
| Shares Owned By Insiders | 5.50 % | |||
| Shares Owned By Institutions | 27.56 % | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 46.89 X | |||
| Revenue | 6 M | |||
| Gross Profit | 5.32 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Compugen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Compugen's short interest history, or implied volatility extrapolated from Compugen options trading.
Pair Trading with Compugen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Compugen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compugen will appreciate offsetting losses from the drop in the long position's value.Moving against Compugen Stock
| 0.47 | BLRX | BioLine RX | PairCorr |
| 0.45 | SKBN | Shikun Binui | PairCorr |
The ability to find closely correlated positions to Compugen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Compugen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Compugen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Compugen to buy it.
The correlation of Compugen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Compugen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Compugen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Compugen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Compugen Stock refer to our How to Trade Compugen Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Compugen Stock analysis
When running Compugen's price analysis, check to measure Compugen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compugen is operating at the current time. Most of Compugen's value examination focuses on studying past and present price action to predict the probability of Compugen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compugen's price. Additionally, you may evaluate how the addition of Compugen to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |